KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.
KT621-AD-201
Phase 2 small_molecule active
Quick answer
KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding. for Moderate to Severe Atopic Dermatitis is a Phase 2 program (small_molecule) at Kymera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kymera Therapeutics
- Indication
- Moderate to Severe Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active